Profund Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.06M | Sell |
142,142
-41,410
| -23% | -$594K | 0.08% | 195 |
|
|
2025
Q4 | $2.61M | Buy |
183,552
+100,317
| +121% | +$986K | 0.08% | 151 |
|
|
2025
Q3 | $656K | Sell |
83,235
-4,442
| -5% | -$31.6K | 0.02% | 430 |
|
|
2025
Q2 | $502K | Buy |
87,677
+31,997
| +57% | +$206K | 0.02% | 464 |
|
|
2025
Q1 | $454K | Sell |
55,680
-12,113
| -18% | -$112K | 0.02% | 504 |
|
|
2024
Q4 | $639K | Sell |
67,793
-15,379
| -18% | -$160K | 0.02% | 405 |
|
|
2024
Q3 | $888K | Sell |
83,172
-3,763
| -4% | -$41K | 0.03% | 355 |
|
|
2024
Q2 | $862K | Sell |
86,935
-32,323
| -27% | -$332K | 0.03% | 340 |
|
|
2024
Q1 | $1.4M | Sell |
119,258
-13,148
| -10% | -$168K | 0.05% | 255 |
|
|
2023
Q4 | $1.88M | Buy |
132,406
+10,199
| +8% | +$116K | 0.08% | 184 |
|
|
2023
Q3 | $1.49M | Buy |
122,207
+1,478
| +1% | +$19.1K | 0.08% | 189 |
|
|
2023
Q2 | $1.52M | Buy |
120,729
+7,288
| +6% | +$86.5K | 0.08% | 199 |
|
|
2023
Q1 | $1.26M | Buy |
113,441
+89,783
| +380% | +$1.11M | 0.08% | 238 |
|
|
2022
Q4 | $289K | Buy |
23,658
+1,367
| +6% | +$15.4K | 0.02% | 673 |
|
|
2022
Q3 | $233K | Sell |
22,291
-349
| -2% | -$3.89K | 0.02% | 726 |
|
|
2022
Q2 | $243K | Sell |
22,640
-351
| -2% | -$2.89K | 0.02% | 773 |
|
|
2022
Q1 | $218K | Sell |
22,991
-1,636
| -7% | -$15.3K | 0.01% | 1206 |
|
|
2021
Q4 | $284K | Buy |
24,627
+1,735
| +8% | +$19.3K | 0.01% | 1024 |
|
|
2021
Q3 | $219K | Sell |
22,892
-4,360
| -16% | -$44.6K | 0.01% | 1196 |
|
|
2021
Q2 | $262K | Buy |
27,252
+2,371
| +10% | +$23.1K | 0.01% | 1182 |
|
|
2021
Q1 | $246K | Buy |
24,881
+1,372
| +6% | +$21.2K | 0.01% | 1131 |
|
|
2020
Q4 | $543K | Buy |
23,509
+1,371
| +6% | +$28K | 0.02% | 510 |
|
|
2020
Q3 | $313K | Sell |
22,138
-1,164
| -5% | -$17K | 0.02% | 648 |
|
|
2020
Q2 | $351K | Buy |
23,302
+1,571
| +7% | +$19.1K | 0.02% | 510 |
|
|
2020
Q1 | $201K | Sell |
21,731
-3,078
| -12% | -$29.3K | 0.02% | 651 |
|
|
2019
Q4 | $242K | Buy |
24,809
+4,352
| +21% | +$39.8K | 0.01% | 1064 |
|
|
2019
Q3 | $164K | Sell |
20,457
-2,403
| -11% | -$26.1K | 0.01% | 1201 |
|
|
2019
Q2 | $285K | Buy |
22,860
+2,546
| +13% | +$32.3K | 0.01% | 951 |
|
|
2019
Q1 | $276K | Sell |
20,314
-7,116
| -26% | -$86.9K | 0.01% | 962 |
|
|
2018
Q4 | $263K | Sell |
27,430
-10,251
| -27% | -$113K | 0.02% | 851 |
|
|
2018
Q3 | $456K | Buy |
+37,681
| New | +$527K | 0.02% | 894 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Profund Advisors's FOLD Position: Q1 2026 in Review
Profund Advisors reduced its Amicus Therapeutics (FOLD) stake by 23% in Q1 2026, selling an estimated $594K and leaving 142,142 shares worth $2.06M. The position accounts for 0.08% of the portfolio, ranked #195.
Profund Advisors first reported a position in FOLD in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.61M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Profund Advisors held 142,142 shares of Amicus Therapeutics worth $2.06M as of Q1 2026.
- Profund Advisors sold 41,410 Amicus Therapeutics shares in Q1 2026, an estimated $594K.
- Amicus Therapeutics made up 0.08% of Profund Advisors's portfolio in Q1 2026, its #195 holding.
- Profund Advisors first reported a position in Amicus Therapeutics in Q3 2018 and has held it in 31 quarters since.
- Profund Advisors's Amicus Therapeutics position peaked at $2.61M in Q4 2025.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.